Abstract:Human carbonyl reductase 1 (CBR1), a member of the short-chain dehydrogenase/reductase superfamily, reduces anthracycline anticancer drugs to their less potent anticancer C-13 hydroxy metabolites, which are linked with pathogenesis of cardiotoxicity, a side effect of the drugs. CBR1 inhibitors are thought to be promising agents for adjuvant therapy with a twofold beneficial effect in prolonging the anticancer efficacy of the anthracyclines while decreasing cardiotoxicity. In order to search for new potential inhibitors of CBR1, we synthesized a series of des-methoxyphenyl derivatives of (Z)-2-(4-methoxyphenylimino)-7-hydroxy-N-(pyridin-2-yl)-2H-chromene-3-carboxamide (1) that was developed previously as a potent inhibitor of aldo-keto reductase (AKR) 1B10 and AKR1B1. Among the newly synthesized inhibitors, 8-hydroxy-2-imino-2H-chromene-3-carboxylic acid (2-chlorophenyl)amide (13h) was the most potent competitive inhibitor of CBR1, showing a Ki value of 15 nM. 13h also showed high selectivity to CBR1 over its isozyme CBR3 and other enzymes with CBR activity (AKR1B1, AKR1B10, AKR1C1, AKR1C2, AKR1C4, DXCR and DHRS4). Furthermore, 13h inhibited the cellular metabolism by CBR1 at its concentration of 4 μM. The structure-activity relationship of the derivatives, site-directed mutagenesis of putative binding residues (Met141 and Trp229) and molecular docking of 13h in CBR1 revealed that the interactions of 13h with the substrate-binding residues (Ser139, Met141, Tyr193 and Trp229) are important for the tight binding.

Design and Synthesis of Polyhydroxy Steroids As Selective Inhibitors Against AKR1B10 and Molecular Docking.

Synthesis and biological evaluation of steroidal derivatives as selective inhibitors of AKR1B10

Correction to Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy Against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells.

Overview of human 20 alpha-hydroxysteroid dehydrogenase (AKR1C1): Functions, regulation, and structural insights of inhibitors

Discovery of Novel Aldo-Keto Reductase 1C3 Inhibitors As Chemotherapeutic Potentiators for Cancer Drug Resistance.

Inhibitor Selectivity Between Aldo – Keto Reductase Superfamily Members AKR 1 B 10 and AKR 1 B 1 : Role of Trp 112 ( Trp 111 )

In silico study of novel alpha tocopheroids as effective inhibitors of aldo-keto reductase 1c3 (AKR1C3) enzyme

Development of highly potent and specific AKR1C3 inhibitors to restore the chemosensitivity of drug-resistant breast cancer

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Screening, Synthesis, Crystal Structure, and Molecular Basis of 6-Amino-4-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitriles As Novel AKR1C3 Inhibitors.

Structure-based Design, Synthesis and Biological Evaluation of Diphenylmethylamine Derivatives As Novel Akt1 Inhibitors

Development of Biaryl-Containing Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors for Reversing AKR1C3-Mediated Drug Resistance in Cancer Treatment

Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment

Synthesis, Activity Evaluation, and Docking Analysis of Barbituric Acid Aryl Hydrazone Derivatives As RSK2 Inhibitors

Structural Basis for the Inhibition of AKR1B10 by Caffeic Acid Phenethyl Ester (CAPE).

Design, Synthesis and Biological Evaluation of Novel Chroman Derivatives As Non-Selective Acetyl-Coa Carboxylase Inhibitors

Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel Benzopyran and Phenylpyrazole Derivatives as Akt Inhibitors.

Design, Synthesis and Biological Evaluation of Novel 3-Oxo-4-oxa-5α-androst-17β-amide Derivatives As Dual 5Α-Reductase Inhibitors and Androgen Receptor Antagonists.

Synthesis of 8-Hydroxy-2-iminochromene Derivatives As Selective and Potent Inhibitors of Human Carbonyl Reductase 1.

Investigation of the Potential of Bile Acid Methyl Esters as Inhibitors of Aldo‐keto Reductase 1C2: Insight from Molecular Docking, Virtual Screening, Experimental Assays and Molecular Dynamics

Overview of AKR1C3: Inhibitor Achievements and Disease Insights.